Children's cough syrup recalled nationwide over bacterial risk that ‘can cause death'
Medtech Products issued a nationwide recall of its Little Remedies Honey Cough Syrup after discovering a bacterium that can cause serious foodborne illness, according to a U.S. Food and Drug Administration advisory.
The voluntary recall affects five lots of the syrup, sold in 4-fluid-ounce amber bottles and distributed in stores — including Walgreens, Target, CVS, and Safeway — and online between December 14, 2022, and June 4, 2025.
The affected product bears the UPC 7-56184-10737-9 and includes lot numbers 0039 (exp. 11/2025), 0545 (01/2026), 0640 (02/2026), 0450 (05/2026), and 1198 (12/2026). The recall extends to all lots still within their expiration dates.
The bacteria found in the cough syrup, Bacillus cereus, can cause two distinct types of gastrointestinal illness. One type leads to nausea, vomiting and stomach cramps within hours of ingestion. The other manifests later, often with diarrhea and abdominal discomfort.
'Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death,' the FDA warned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 hours ago
- Miami Herald
Bacteria that can cause vomiting, diarrhea gets kids' cough syrup recalled
Parents, guardians and all who care for kids should check their medicine cabinets after a children's cough syrup was recalled for a foodborne bacteria that can cause myriad problems. And, in extreme cases, cause death. Medtech Products' recall notice, posted to the FDA website, said it recalled five lots of Little Remedies Honey Cough Syrup for the 'presence of Bacillus cereus and loss of shelf-stability.' That bacteria can bring on two kinds of foodborne illnesses. 'One type is characterized by nausea, vomiting, and stomach cramps that can start one to six hours after eating or drinking contaminated food,' Medtech's notice said. 'The second type can cause stomach cramps and diarrhea that can start eight to 16 hours after eating or drinking contaminated food. 'Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death.' Recalled lot Nos. are 0039, expiration date 11/2025; 0545, expiration date 1/2026; 0640, expiration date 2/2026; 0450, expiration date 5/2026; and 1198, expiration date 12/2026. For refunds, Medtech is asking customers to go to the Prestige Brands website, email medicalaffairs@ or call 800-754-8853, Monday through Friday, 8:30 a.m. to 5:30 p.m., Eastern time. Any medical problems should be taken to a medical professional first. Then notify the FDA's MedWatch program by filling out a report online. After that, tell Medtech.
Newsweek
9 hours ago
- Newsweek
Natiowide Shrimp Recall Update as FDA Sets Highest Alert
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has issued its highest risk classification for approximately 64,000 pounds of recalled shrimp sold across the United States. The FDA's Class I recall — reserved for fears of serious health issues or death — applies to about 3,200 cases of frozen shrimp distributed to Whole Foods stores. Tri-Union Frozen Products, also known as Chicken of the Sea Frozen Foods, issued a voluntary recall for its "Raw P&D Tail-On White Shrimp" due to "undeclared sulfites" on May 6. The FDA designated it a Class I recall on June 24. Newsweek contacted Tri-Union and Whole Foods via email on Wednesday for further details. Stock image. The FDA has issued a Class I risk classification for approximately 64,000 pounds of recalled shrimp sold across the United States. Stock image. The FDA has issued a Class I risk classification for approximately 64,000 pounds of recalled shrimp sold across the United States. Getty Images Why It Matters A Class I risk classification represents "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death," according to the FDA. This recall impacted consumers nationwide who purchased shrimp from Whole Foods, heightening public safety concerns regarding seafood contamination and mislabeling. Prompt notification enables consumers to avoid illness and demonstrates the role of regulatory agencies in maintaining public safety. What To Know The FDA notice said the shrimp were "sold exclusively to Whole Foods USA." "Whole Foods uses some of the product for its retail in-store deli," it added. "Product was distributed to various Whole Foods stores across the country. The remaining portion of the lot, is passed through to a downstream customer in Canada." Key Recall Details The product description reads: "Frozen Shrimp - packaged in 5lb frozen IQF blocks/4 blocks to a case." Unlabeled case packaging reads: "Raw P&D Tail-On White Shrimp." UPC code: 1 08432370 0405 5 Lot numbers: 669/18WH/124; 669/19WH/134; 669/20WH144; 669/30VH/127; 669/01HH/003; 669/03HH011 Best-by dates: July 18, 2026; July 19, 2026; July 20,2026; September 30, 2026; October 01, 2026; October 03, 2026. Why Was the Shrimp Recalled? The shrimp contained "undeclared sulfites," the FDA said. Sulfites are a group of sulfur-based compounds commonly used in foods as preservatives and to maintain color and freshness. They are often found in processed foods, wines, dried fruit, and some seafood products. The FDA requires that foods containing at least 10 parts per million (ppm) of sulfites to declare this on their packaging, as exposure can affect consumers with sensitivities. While most individuals can tolerate sulfites without issue, people with sulfite sensitivity — especially those with asthma — may experience serious reactions. Symptoms may include difficulty breathing, hives, abdominal pain, or, rarely, life-threatening anaphylaxis. Serious reactions can occur within minutes of exposure. The FDA estimates that less than one percent of the U.S. population is sulfite-sensitive, though the number is higher among individuals with asthma. The U.S. Centers for Disease Control and Prevention reported that approximately 25 million Americans had asthma as of 2021. Of these, research indicates that about 5-10 percent (or approximately 1.25–2.5 million people) could react to sulfites. What Happens Next The FDA said the recall remains ongoing.
Business Wire
11 hours ago
- Business Wire
Stryker receives FDA clearance for Incompass Total Ankle System
PORTAGE, Mich.--(BUSINESS WIRE)--Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement. 'Incompass reflects our commitment to redefining what's possible in total ankle replacement,' said Adam Jacobs, vice president and general manager of Stryker's Foot & Ankle business. 'By building on decades of clinical experience and leveraging extensive data insights, we're setting a new standard—one that empowers surgeons to deliver more personalized care with greater efficiency and confidence.' Incompass incorporates Adaptis® Boney Ingrowth Technology and redesigned instrumentation to support long-term fixation, surgical flexibility and streamlined workflow. Developed to address key challenges in total ankle replacement, including intraoperative adaptability and procedural efficiency, the system is informed by data from more than 85,000 CT scans¹ and 100,000 clinical cases.¹ It also offers a broad range of implant and instrumentation options to support patient-specific care. Built using the Stryker Orthopaedic Modeling & Analytics (SOMA) platform in combination with arthritic ankle scans from the company's Prophecy Surgical Planning System, Incompass provides a continuum of implant and instrument options designed to accommodate both surgeon preference and patient anatomy. System enhancements include a redesigned alignment system for greater control across multiple planes, updated implant holders and trial tools for improved handling, and instrumentation refinements designed to reduce surgical steps and set up time. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at Copyright © 2025 Stryker Content ID: FA-INCO-PRESS-2016296 References: 1. Based on internal data as of 5/1/2025.
